To include your compound in the COVID-19 Resource Center, submit it here.

Telotristat etiprate: Preliminary Phase II data

Preliminary data from a 12-week, open-label, dose-escalation, European Phase II trial showed that 5 of 6 evaluable

Read the full 177 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE